We successfully developed the PDT/CAP combination therapy to enhance the therapeutic efficacy on cervical cancer using the PPHE polymeric nanoparticles, in which cancer-targeting ligands (i.e., HA and EAE7) are introduced via the LBL self-assembly method for the HER3/CD44 dual targeting of cervical cancer cells. This evidence concerns the gene ERBB3 and cervical cancer.